

IN THE CLAIMS

Please amend the following claims:

b¹ 31. (Amended) An isolated soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex; and

wherein the heterodimeric or multimeric receptor complex binds a ligand comprising a polypeptide of SEQ ID NO:10, or antagonizes the ligand activity.

b² 33. (Amended) An isolated polypeptide according to claim 31, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex comprising a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4).

b³ 37. (Amended) An isolated heterodimeric or multimeric soluble receptor complex according to claim 35, further comprising a soluble IL-2R γ receptor polypeptide (SEQ ID NO:4).

b⁴ 49. (Amended) An isolated heterodimeric receptor complex according to claim 48, wherein the heterodimeric receptor complex binds a ligand comprising a polypeptide of SEQ ID NO:10, or antagonizes the ligand activity.

Please add the following new claims:

b⁵ -- 61. An isolated heterodimeric receptor complex consisting of two soluble receptor subunits, wherein the first soluble receptor subunit consists of a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, and the second receptor subunit consists of a soluble receptor polypeptide comprising soluble IL-2R γ receptor polypeptide (SEQ ID NO:4).

62. An isolated heterodimeric receptor complex according to claim 61, wherein the heterodimeric receptor complex binds a ligand comprising a polypeptide of SEQ ID NO:10 or antagonizes the ligand activity.

63. An isolated heterodimeric receptor complex according to claim 61, wherein at least one of the soluble receptor subunits further comprises an affinity tag, label, chemical moiety, toxin, biotin/avidin label, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, toxin, cytotoxic molecule or an immunoglobulin Fc domain.

64. An isolated heterodimeric receptor complex according to claim 61, wherein at least one of the soluble receptor subunits further comprises a transmembrane domain.

65. An isolated heterodimeric receptor complex according to claim 64, wherein the transmembrane domain is from a class I cytokine receptor.

66. An isolated heterodimeric receptor complex according to claim 61, wherein at least one of the soluble receptor subunits further comprises a transmembrane domain, and an intracellular domain from a cytokine receptor.

67. An isolated polypeptide according to claim 66, wherein the intracellular domain is from a class I cytokine receptor.

68. An isolated heterodimeric receptor complex according to claim 61, wherein both of the soluble receptor subunits further comprise a transmembrane domain.

69. An isolated heterodimeric receptor complex according to claim 68, wherein the transmembrane domain is from a class I cytokine receptor.

70. An isolated heterodimeric receptor complex according to claim 61, wherein both of the soluble receptor subunits further comprise a transmembrane domain, and an intracellular domain from a cytokine receptor.

71. An isolated polypeptide according to claim 70, wherein the intracellular

domain is from a class I cytokine receptor. --

BS
concluded